Metformin Glipizide Tablets

Metformin hydrochloride and glipizide in metformin hydrochloride glipizide tablets are two widely used and effective oral hypoglycemic drugs. The combination of the two has a synergistic hypoglycemic effect. In addition to reducing the initial dose of the two drugs, it also increases the extensiveness of the drugs, providing a new way for the treatment of diabetes. Glipizide is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of action is to promote endogenous insulin secretion. It takes effect 30 minutes after oral administration and lasts for about 16-24 hours. Metformin hydrochloride is a biguanide oral hypoglycemic drug that reduces blood sugar levels by reducing liver glucose output and increasing peripheral tissue absorption of sugar. It can promote endogenous insulin secretion, reduce fat synthesis, maintain or reduce body weight, and thus reduce the risk factors of arteriosclerosis. The combined use of the two drugs not only enhances the activity of endogenous insulin, but also reduces the occurrence of side effects such as hypoglycemia.

Glipizide 2.5mg/Metformin hydrochloride 250mg

This product is white tablets.

When using this product alone, it is recommended to combine it with diet and exercise therapy to achieve the effect of controlling blood sugar in non-insulin-dependent (type 2) diabetes. This product can also be used in combination with sulfonylurea hypoglycemic drugs or insulin to control type 2 diabetes.

There is no fixed dose for the treatment of hyperglycemia with this drug in type 2 diabetes. The dose must be individualized based on action and tolerance without exceeding the maximum recommended dose, which is 2000 mg/day. This drug is usually taken as a single dose with dinner. In order to reduce the occurrence of gastrointestinal complications and to use the minimum dose of the drug to adequately control the patient's blood sugar, it should be taken from a low dose and gradually increased. At the beginning of treatment and during the dose adjustment period (see recommended medication schedule), fasting blood sugar can be used to determine the therapeutic response of this drug and to determine the patient's minimum effective dose. Thereafter, glycated hemoglobin should be measured every three months. Whether used alone or in combination with sulfonylurea drugs and insulin, the goal of treatment is to use the lowest effective dose to reduce fasting blood sugar and glycated hemoglobin levels to normal or near normal levels. Monitoring blood sugar and glycated hemoglobin can determine primary failure and secondary failure. The former refers to the inability to effectively lower blood sugar even with the maximum recommended dose of the drug, while the latter refers to the loss of satisfactory blood sugar-lowering effect after the initial effective period. Short-term use of this drug is effective for patients who usually control blood sugar well with diet alone but have temporary blood sugar elevation. Recommended Dosing Plan Adults - Generally, there is no obvious clinical reaction at doses below 1500 mg/day. However, in order to reduce gastrointestinal adverse reactions, it is recommended to start with a small amount and gradually increase the dose. Usually the starting dose of metformin hydrochloride extended-release tablets is 500 mg, taken once a day with dinner. The dose is increased by 500 mg each week, to a maximum dose of 2000 mg, taken once a day with dinner. If blood sugar is still not satisfactorily controlled with 2000 mg, once a day, you can consider switching to 1000 mg, twice a day for experimental treatment. If a larger amount of metformin is needed, the maximum dose of 2550 mg/day of metformin hydrochloride tablets should be used, taken in divided doses. A randomized trial of switching from metformin hydrochloride tablets to metformin hydrochloride extended-release tablets showed that patients receiving metformin hydrochloride tablets can safely switch to metformin hydrochloride extended-release tablets once a day at the same dose, up to 2000 mg once a day. Blood sugar should be closely monitored after the switch, and the dose should be adjusted accordingly. Switching from other hypoglycemic therapies Except for chlorpropamide, patients usually do not need a conversion period when switching from other oral hypoglycemic drugs to this product. Patients taking chlorpropamide should pay close attention in the first 2 weeks of switching to this product, because chlorpropamide stays in the body for a long time, which can easily lead to overdose of the drug and hypoglycemia. Combination with sulfonylureas: If patients do not respond to the maximum recommended dose of this product after several weeks, they should consider gradually adding sulfonylurea oral hypoglycemic drugs while maintaining the maximum dose treatment, unless the patient has primary or secondary failure to sulfonylurea drugs. Currently, there are only clinical and pharmacokinetic data on the interaction between metformin and glibenclamide (glyburide). When this product is taken in combination with sulfonylureas, satisfactory blood sugar control can be achieved by adjusting the doses of the two drugs. The risk of hypoglycemia caused by sulfonylureas persists and even increases with combined treatment with this product, and appropriate prevention should be carried out. (See the packaging instructions of the selected sulfonylurea drug). If patients cannot achieve satisfactory blood sugar control after 1 to 3 months of combined treatment with the maximum dose of this product and the maximum dose of oral sulfonylurea drugs, consider changing the treatment method, including combining this product, insulin treatment or insulin alone. Combination with insulin in adults: The insulin dose can be maintained when starting treatment with this product. The starting dose of this product for patients treated with insulin should be 500 mg, once a day. If the patient's response is not enough, increase 500 mg after 1 week, and then increase 500 mg every week until satisfactory blood sugar control is achieved. The recommended maximum daily dose is 2000 mg. When the fasting blood sugar of patients using this product in combination with insulin drops below 120 mg/dl, it is recommended to reduce the insulin dose by 10% to 25%. Or follow the doctor's advice. Individualized adjustments should continue to be made based on the response to lower blood sugar.

1. Common symptoms include: nausea, vomiting, diarrhea, metallic taste in the mouth. 2. Sometimes there is weakness, tiredness, dizziness, and rash. 3. Although the incidence of lactic acidosis is very low, it should be paid attention to. Clinical manifestations include vomiting, abdominal pain, hyperventilation, mental disorder, and increased lactic acid concentration in the blood that cannot be explained by uremia, ketoacidosis or salicylic acid poisoning. 4. It can reduce the intestinal absorption of vitamin B12, reduce hemoglobin, produce megaloblastic anemia, and also cause malabsorption.

Patients with the following diseases are contraindicated to use metformin hydrochloride: 1. Kidney disease or renal insufficiency caused by cardiovascular failure, acute myocardial infarction and sepsis (such as blood creatinine level ≥1.5mg/dl (male), ≥1.4mg/dl (female) or abnormal creatinine clearance). 2. Congestive heart failure requiring drug treatment, and other serious cardiopulmonary diseases. 3. Patients who have received radiotherapy including parenteral administration of iodinated contrast agents should suspend the use of metformin hydrochloride, because the use of such products can cause acute changes in renal function. 4. Known allergy to metformin hydrochloride and any ingredient in this product. 5. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. 6. Severe

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. Single-dose combined use of metformin and glibenclamide did not change the pharmacokinetic parameters of metformin. 2. When metformin was used in combination with furosemide (furosemide), the AUC of metformin increased, but renal clearance did not change; at the same time, the Cmax and AUC of furosemide decreased, the terminal half-life shortened, and renal clearance did not change. 3. Cationic drugs secreted by the renal tubules (such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin) may theoretically compete with metformin for the renal tubular transport system and interact with each other. Therefore, it is recommended to closely monitor and adjust the dose of this product and/or interacting drugs. 4. When metformin was used in combination with cimetidine, the plasma and whole blood AUC of metformin increased, but when the two drugs were used alone, no change in the elimination half-life of metformin was observed. The pharmacokinetics of cimetidine did not change. 5. If you are taking certain drugs that may cause blood sugar to rise at the same time, such as thiazides or other diuretics, glucocorticoids, phenothiazines, thyroid preparations, estrogen, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid, you should monitor blood sugar closely, and pay close attention to the occurrence of hypoglycemia after these drugs are discontinued. 6. Metformin does not bind to plasma proteins. Therefore, drugs that are highly bound to proteins, such as salicylates, aminobenzenesulfonic acid, chloramphenicol, probenecid, etc., are less likely to interact with sulfonylureas, which are mainly bound to serum proteins. 7. Except for chlorpropamide, patients usually do not need a conversion period when switching from other oral hypoglycemic drugs to this product. Patients taking chlorpropamide should pay close attention to the first 2 weeks of switching to this product, because chlorpropamide has a long retention in the body, which can easily lead to overdose of the drug and hypoglycemia. 8. When healthy people take nifedipine and metformin together as a single dose, the peak plasma concentration and area under the plasma concentration-time curve of metformin increase by 20% and 9% respectively, and the excretion in urine increases, but the Tmax and half-life are not affected. 9. Metformin increases the anticoagulant tendency of warfarin. 10. The combination of resin drugs and this product can reduce the absorption of metformin.

Keep away from light and store in sealed container.

Metformin 250 mg, glipizide 2.5 mg

24 months

TC Pharmaceuticals (Jiangsu) Co., Ltd.

• Founded in:

  1994-12-12

• Address:

  No. 191, Jinyang West Road, Lujia Town, Kunshan City, Jiangsu Province

• Tax NO.:

  91320583608280290E

• Registered Funds:

  126.271311 yuan

• Website:

  Log in to view

• Email:

  Log in to view